Cargando…

Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types

PURPOSE: The efficacy and safety of regorafenib have been demonstrated in phase 3 trials for multiple tumor types, including metastatic colorectal cancer (mCRC) (CORRECT [NCT01103323]; CONCUR [NCT01584830]), advanced gastrointestinal stromal tumor (GIST) (GRID [NCT01271712]), and hepatocellular carc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hofheinz, Ralf-Dieter, Bruix, Jordi, Demetri, George D, Grothey, Axel, Marian, Marisca, Bartsch, Jennifer, Odom, Dawn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285228/ https://www.ncbi.nlm.nih.gov/pubmed/34285574 http://dx.doi.org/10.2147/CMAR.S305939

Ejemplares similares

Molecular profiling in the treatment of colorectal cancer: focus on regorafenib
por: Yan, Yiyi, et al.
Publicado: (2015)

The success of regorafenib in hepatocellular carcinoma in a world of failures. Learnings for future developments
por: Reig, Maria, et al.
Publicado: (2017)

The effect of gastrectomy on regorafenib exposure and progression‐free survival in patients with advanced gastrointestinal stromal tumours
por: Lubberman, Floor J.E., et al.
Publicado: (2019)

Severe and delayed-onset acneiform eruptions as an adverse reaction to regorafenib
por: Otsuka, Haruhiko, et al.
Publicado: (2022)

Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations
por: Yoshino, Takayuki, et al.
Publicado: (2014)

Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma
por: Tutusaus, Anna, et al.
Publicado: (2018)

Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule
por: Grimaudo, Maria Susanna, et al.
Publicado: (2023)

Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models
por: Cucarull, Blanca, et al.
Publicado: (2020)

Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models
por: Zopf, Dieter, et al.
Publicado: (2016)

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
por: Kelley, Robin K., et al.
Publicado: (2020)

Erythema multiforme induced by regorafenib
por: Matsunaga, Mototsugu, et al.
Publicado: (2017)

Interaction Between Sex and Organic Anion‐Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib‐N‐Oxide and Regorafenib‐Glucuronide in Mice
por: Fu, Qiang, et al.
Publicado: (2019)

Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
por: Kissel, Maria, et al.
Publicado: (2017)

Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer
por: Sastre, J., et al.
Publicado: (2014)

Real-Life Experience of Regorafenib in Patients With Advanced Hepatocellular Carcinoma
por: Hou, Jing-Yu, et al.
Publicado: (2022)

Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer
por: Huynh, Hung, et al.
Publicado: (2015)

Treatment of lymphomatous and leukemic meningitis with liposomal encapsulated cytarabine
por: Kripp, Melanie, et al.
Publicado: (2008)

Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study
por: Huang, Jingjun, et al.
Publicado: (2022)

Incidence and risk of regorafenib-induced hepatotoxicity
por: Zhao, Bin, et al.
Publicado: (2017)

Experience with regorafenib in the treatment of hepatocellular carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

Characterization of Glioblastoma Cells Response to Regorafenib
por: Mongiardi, Maria Patrizia, et al.
Publicado: (2022)

Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab
por: Kim, George P, et al.
Publicado: (2008)

Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice
por: Grünewald, Sylvia, et al.
Publicado: (2023)

Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study
por: Brodowicz, Thomas, et al.
Publicado: (2020)

Prevention and management of adverse events related to regorafenib
por: De Wit, Mieke, et al.
Publicado: (2013)

Correction: Incidence and risk of regorafenib-induced hepatotoxicity
por: Zhao, Bin, et al.
Publicado: (2019)

Targeting gastrointestinal stromal tumors: the role of regorafenib
por: Schroeder, Brett, et al.
Publicado: (2016)

Study on efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with regorafenib and PD-1 antibody versus continued TACE combined with regorafenib in patients with hepatocellular carcinoma after failed second-line treatment with regorafenib
por: Wang, Haochen, et al.
Publicado: (2022)

Correction: Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice
por: Grünewald, Sylvia, et al.
Publicado: (2023)

Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer
por: Ravi, Sujan, et al.
Publicado: (2014)

A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies
por: How, Joan, et al.
Publicado: (2022)

The Role of Regorafenib in the Management of Advanced Gastrointestinal Stromal Tumors: A Systematic Review
por: Khachatryan, Vahe, et al.
Publicado: (2022)

A multi-center retrospective study on the efficacy and safety of regorafenib vs. regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinoma
por: Yan, Tao, et al.
Publicado: (2023)

Critical appraisal of the use of regorafenib in the management of colorectal cancer
por: Festino, Lucia, et al.
Publicado: (2013)

Regorafenib: Adding to the Armamentarium for Refractory Colorectal Cancer and GIST
por: Roman, Danielle, et al.
Publicado: (2013)

SHP-1 is a target of regorafenib in colorectal cancer
por: Fan, Li-Ching, et al.
Publicado: (2014)

Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
por: Melosky, Barbara
Publicado: (2016)

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications
por: Personeni, Nicola, et al.
Publicado: (2018)

Practical considerations in the use of regorafenib in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2020)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
por: Kawakami, Kazuyoshi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dsvrrauve1ahhjfneis7cvd4a7